Tri-Agonist for the GLu, GLP-1 and NPY2 Receptors

Robert Doyle (Inventor)

Research output: Patent


A monomeric peptide that functions as an agonist for the glucagon receptor (GluR), the glucagon-like peptide 1 receptor (GLP1-R) and neuropeptide Y2 receptor (NPY2-R). The peptide thus targets three of the receptors involved glucoregulation and appetite regulation to more efficiently and completely facilitate weight loss in, among others, type II diabetic patients while also being capable of stimulating a reduction in appetite to complement the weight loss results.
Original languageEnglish (US)
StatePublished - Jul 11 2019


Dive into the research topics of 'Tri-Agonist for the GLu, GLP-1 and NPY2 Receptors'. Together they form a unique fingerprint.

Cite this